Results 141 to 150 of about 264,257 (370)

Predictors of delay in diagnosis and treatment in diffuse large B‐cell lymphoma and impact on survival [PDF]

, 2014
Anna S. Nikonova, Hany R. Guirguis, Rena Buckstein, Matthew C. Cheung   +3 more
openalex   +1 more source

Intracellular self‐assembled nanoneedles for efficient lysosomal escape and CRISPR/Cas9 mediated gene editing

BMEMat, EarlyView.
PlaMnB was formed by cytolysin A‐tumor homing peptides (THP)‐modified bacterial membranes encapsulating the clustered regularly interspaced short palindromic repeat/CRISPR‐associated protein (CRISPR/Cas9) plasmid and manganese dioxide. THP‐containing bacterial membrane enhances PlaMnB vascular permeability and tumor targeting, and after cellular ...
Chen Zhang, Nan Zhang, Ruiqi Yang, Qian Qiu, Jiaying Huang, Jingang Liu, Silu Li, Jonathan F. Lovell, He Ren, Yumiao Zhang   +9 more
wiley   +1 more source

HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism

Cancer Communications, EarlyView.
Abstract Background Brain metastasis, a leading cause of death in patients with lung adenocarcinoma (LUAD), arises from tumor cells adapting to the unique microenvironment of the brain through metabolic remodeling regulated by key oncogenes. Here, we aimed to determine the role of high mobility group protein box 3 (HMGB3) in regulating tumor cell ...
Huanhuan Cui, Yuechao Yang, Sen Li, Yan Hao, Mingtao Feng, Changshuai Zhou, Xin Chen, Yang Gao, Lei Chen, Xiaojun Wu, Weiguo Hu, Liangdong Li, Yiqun Cao   +12 more
wiley   +1 more source

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Haematologica, 2017
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim   +11 more
doaj   +1 more source

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

Journal of Clinical Oncology, 2018
PURPOSE Outcomes for patients with diffuse large B-cell lymphoma remain heterogeneous, with existing methods failing to consistently predict treatment failure. We examined the additional prognostic value of circulating tumor DNA (ctDNA) before and during
D. Kurtz, F. Scherer, M. Jin, Joanne Soo, A. Craig, M. S. Esfahani, J. Chabon, H. Stehr, C. Liu, R. Tibshirani, L. Maeda, Neel K. Gupta, M. Khodadoust, R. Advani, R. Levy, Aaron M. Newman, U. Dührsen, A. Hüttmann, M. Meignan, R. Casasnovas, J. Westin, M. Roschewski, W. Wilson, G. Gaidano, D. Rossi, M. Diehn, Ash A. Alizadeh   +26 more
semanticscholar   +1 more source

Treatment of Diffuse Large B Cell Lymphoma

The Korean Journal of Internal Medicine, 2012
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in combination with chemotherapy.
openaire   +2 more sources

Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non‐small cell lung cancer: a prospective phase II study (GASTO‐1053)

Cancer Communications, EarlyView.
Abstract Background The prognosis for non‐small cell lung cancer (NSCLC) patients with extensive brain metastases (BMs) treated with radiotherapy alone remains poor. Based on the synergistic potential of radiotherapy and angiogenesis inhibitors, we initiated this phase II study to assess the efficacy and safety of combining bevacizumab (Bev) with ...
Rui Zhou, Shiyang Zheng, Daquan Wang, Fang Dong, Hongmei Zhang, Tao Zhang, Qiaoting Luo, Biaoshui Liu, Hui Liu, Jun Zhang, Fangjie Liu, Bin Wang, Likun Chen, Yonggao Mou, Kangqiang Peng, Bo Qiu, Hui Liu   +16 more
wiley   +1 more source

Refractory diffuse large B-cell Lymphoma

Journal of Taibah University Medical Sciences, 2023
Hajar Masrour, Latifa Lerhrib, Sanaa Bouchnafati, Widad Rhandour, Mounia Bouzayd, Laila Abarkan, Anas Oudrhiri, Nabil Al Saddiq, Rim Hanini, Yassine Chekkori, Falah Eddine Tohir, Ouazzani, Naoual Oubelkacem, Noufissa Alami Drideb, Zineb Khammar, Rhizlane Berrady   +15 more
doaj   +1 more source

Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP

Haematologica, 2010
Background BCL6 gene rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma, a malignancy characterized by genetic heterogeneity and wide variability in clinical outcome.
Jesse Shustik, Guangming Han, Pedro Farinha, Nathalie A. Johnson, Susana Ben Neriah, Joseph M. Connors, Laurie H. Sehn, Douglas E. Horsman, Randy D. Gascoyne, Christian Steidl   +9 more
doaj   +1 more source

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

ChemBioChem, EarlyView.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh, Rupesh R. Kurhade, Abrar A. M. Siddiqui, Shaikh Shahbaz A. Majeed, Thomas J. Webster, Mohammad Intakhab Alam, Abdul Wasy Zia, Md. Faiyazuddin   +7 more
wiley   +1 more source